Day: December 8, 2022

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — – NetworkNewsAudio – Knightscope, Inc. (NASDAQ: KSCP) announces the availability of a broadcast titled, “The Rise of the Robots — Already Here, More Are Coming.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/YPxvg Given the sheer volume of crimes committed today, there’s a growing demand to employ robots equipped with high-definition cameras, streaming and recording, with capabilities to surveil public and private areas in a bid to deter, intervene, capture and prosecute offenders. Robots aren’t intended to be a replacement for human security personnel, rather high-tech assistants that are incorruptible, cost efficient and relentlessly on patrol. A global leader in the development of autonomous security...

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in unified critical communications systems and solutions that help keep people safe, today announced that Richard Danforth, CEO, and Dennis Klahn, CFO, will participate in the Imperial Capital 2022 Security Investor Conference (SIC) being held at the InterContinental New York Barclay in New York City on December 15, 2022. The Company will host a group presentation on Thursday, December 15, 2022, at 4:15 p.m. ET in the Empire I Room and conduct one-on-one meetings the same day. A webcast of the Company’s presentation at the conference will be available on Genasys’ Investor Relations website under the Events and Presentations tab on the following link: https://genasys.com/investors/presentations-events/. SIC is consistently the...

DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETING MEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHSMENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, is pleased to report independent data addressing a frequent question from eyecare practitioners (ECPs) and patients regarding the treatment of meibomian gland disease (MGD) using the TearCare® System: How long does a single treatment last? Clinical outcomes for 78 dry eye patients (156 eyes) treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare® System and were presented...

Denver, CO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Umbra Applied Technologies Group, Inc’s (OTC Pink: UATG) subsidiary, H2O Processing, announced today that it has been contracted by Bellows Operating Salt Water Discharge (BOSWD to treat heavily iron contaminated crude oil. Under the agreement, H2O Processing will treat a minimum of 1,000 barrels of crude oil daily with an anticipated 1,500 bbls daily based on current production. The newly signed agreement allows for increased production of up to 8,000 bbls a day totaling more than $15 million dollars in annual revenue. Initial anticipated monthly production is valued to begin at more than $240,000 a month. H2O Processing Chief Executive Officer, Stan Abrams stated, “We are pleased to have BOSWD join H2O Processing to extract iron from the crude oil.  We have developed a unique process...

LAS VEGAS, Dec. 08, 2022 (GLOBE NEWSWIRE) — Live Ventures Incorporated (NASDAQ: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, will issue its financial results for its fiscal fourth quarter and fiscal full year ended September 30, 2022, before the opening of the NASDAQ Stock Market on Thursday, December 15, 2022. The Company will also host a conference call to discuss the results. The conference call will take place on December 15, 2022, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time). The dial-in numbers are as follows:800.274.8461 (U.S.) +1.203.518.9814 (International/caller-paid) Conference ID: LIVEVENTURES Program Title: Live Ventures Incorporated Earnings CallPlease dial in at least 15 minutes in advance, but no sooner than 30 minutes, to ensure you are connected. To listen to the discussion...

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) performed its initial prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The charter for the IDMC provides for periodic reviews by the IDMC for safety, efficacy and futility in addition to the interim and final analyses. The REGAL study is a Phase 3 open-label registrational clinical trial for GPS in AML patients who have achieved complete remission...

FAIRFIELD, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) — Kearny Financial Corp. (NASDAQ GS: KRNY) (the “Company”), the holding company of Kearny Bank (the “Bank”), announced today the completion of a wholesale restructuring related to its investment securities portfolio. In addition, the Company announced the adoption of a company-wide operating efficiency initiative. Wholesale Restructuring The Company executed the sale of $121.4 million of its lower-yielding available-for-sale debt securities for an estimated after-tax loss of approximately $11.0 million. Proceeds from the sale were reinvested in debt securities currently yielding, on average, 440 basis points higher than the securities that were sold. In addition, the Company purchased approximately $100.0 million of debt securities, funded by wholesale borrowings, which will produce...

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. “We are grateful to these distinguished authors for reinforcing the CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial treatment, directly aligning with the value proposition of T2’s technology,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Sepsis continues to exact a heavy human and financial toll, and disproportionally impacts minorities and underserved communities. We believe our FDA-cleared T2Dx Instrument, T2Bacteria...

Expands Commercialization Efforts in Areas with High Unmet Needs IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device. The Company is working with distribution partners to launch the products in these countries and throughout the Middle East and North Africa (MENA) regions. The EZ Detect™ Colon Disease Test is a simple two-minute at-home test for detecting hidden blood in the stool, a primary early warning sign of colorectal cancer. It’s the only test with no stool handling and suitable for national screening campaigns due to its convenience...